NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE
Novo Nordisk A/s Complete list of announcements declared & dividend announcements by Novo Nordisk A/s NVO
Novo Nordisk A/s NVO listed on NYSE and deals in Health Care Major PharmaceuticalsAnnouncements and dividends declared by Novo Nordisk A/s NVO
Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in India
Eli Lilly and Novo Nordisk leaders share their India strategies for weight-loss drugs. They focus on pricing, market expansion and countering generics after semaglutide's patent ends. Both companies aim to increase patient access to their innovative thera
Announcement as on 18 November 2025
Novo Nordisk cuts weight-loss drug Wegovy's price by up to 33% in India, document shows
Novo and Lilly are locked in a race for dominance in India, a key battleground for weight-loss treatments in the booming global market, which analysts estimate could be worth 0 billion annually by the end of the decade. "This appears like prices have be
Announcement as on 11 November 2025
Novo Nordisk slashes Wegovy prices in India by up to 37% to boost sluggish sales of weight-loss drug
According to renowned endocrinologist Dr Shashank Joshi, a steep cut in the prices of Wegovy will help improve access and affordability. “But it has to be cautioned that weight loss drugs are not cosmetic medicines. It has to be prescribed to the right pat
Announcement as on 11 November 2025
Novo Nordisk partners with Emcure to launch weight-loss drug under new brand in India
Novo Nordisk has partnered with Emcure Pharmaceuticals to bring Poviztra, their latest weight-loss medication, to the Indian market. This collaboration builds on Novo Nordisk's prior success with Wegovy and follows Eli Lilly's competition in this space. Af
Announcement as on 10 November 2025
Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India
Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide under the brand name Poviztra in India. This collaboration aims to expand access to the drug by leveraging Emcure's extensive distribu
Announcement as on 10 November 2025
Announcements by Novo Nordisk A/s first page | Next page | Prev page |
NVO Novo Nordisk A/s current price & indicator signals
Recent prices of NVO Novo Nordisk A/s are as follows: Daily volume is divided by 10 day averaged volume
| Date | Close | Range | Change % | Volume |
| 20 Fri Mar 2026 | 36.54 | 35.86 to 37.33 | -1.43% | 1.42 times |
| 19 Thu Mar 2026 | 37.07 | 36.17 to 37.47 | -3.56% | 1.13 times |
| 17 Tue Mar 2026 | 38.44 | 38.30 to 39.27 | -0.36% | 0.65 times |
| 16 Mon Mar 2026 | 38.58 | 37.79 to 38.59 | 1.63% | 0.74 times |
| 13 Fri Mar 2026 | 37.96 | 37.70 to 38.80 | -0.16% | 0.74 times |
| 12 Thu Mar 2026 | 38.02 | 37.85 to 39.02 | -2.14% | 1.1 times |
| 11 Wed Mar 2026 | 38.85 | 38.36 to 39.13 | 0.34% | 0.66 times |
| 10 Tue Mar 2026 | 38.72 | 38.18 to 39.22 | -2.76% | 1.34 times |
| 09 Mon Mar 2026 | 39.82 | 37.68 to 39.88 | 3.21% | 1.26 times |
| 06 Fri Mar 2026 | 38.58 | 38.17 to 38.85 | -1.25% | 0.99 times |
| 05 Thu Mar 2026 | 39.07 | 38.08 to 39.12 | 1.48% | 1.39 times |
| 04 Wed Mar 2026 | 38.50 | 37.29 to 38.60 | 5.02% | 1.73 times |
Videos related to: NVO announcements Novo Nordisk A/s announcements and dividends declared NYSE
Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra
Hindi Video What Is Needed To Succeed In Stock Markets
- NYSE Screeners
- NYSE Daily Screener
- NYSE Weekly Screener
- NYSE Monthly Screener
- Support & Resistance
- NYSE Shares Near Support
- NYSE Shares Near Resistance


